Fas Ligand

Fas Ligand Molekülinformation

Englischer Name	Soluble Fas ligand	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	CD95L，Fas ligand，SPA，FASLG，Soluble Fas ligand，sFasL，Receptor-binding FasL ectodomain，FasL ICD，TNFSF6，Apoptosis antigen ligand，Tumor necrosis factor ligand superfamily member 6，APL，CD178，Fas Ligand (TNF Superfamily， Member 6)，Fas Antigen Ligand，CD95 Ligand，CD95-L，APTL，Mutant Tumor Necrosis Factor Family Member 6，Apoptosis (APO-1) Antigen Ligand 1，CD178 Antigen，ALPS1B，TNLG1A，FasL，Fas Ligand Protein，SPPL2A-processed FasL form，APT1LG1，Tumor Necrosis Factor (Ligand) Superfamily， Member 6，Tumor Necrosis Factor Ligand 1A
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Soluble Fas ligand
Target-Alias	CD95L，Fas ligand，SPA，FASLG，Soluble Fas ligand，sFasL，Receptor-binding FasL ectodomain，FasL ICD，TNFSF6，Apoptosis antigen ligand，Tumor necrosis factor ligand superfamily member 6，APL，CD178，Fas Ligand (TNF Superfamily， Member 6)，Fas Antigen Ligand，CD95 Ligand，CD95-L，APTL，Mutant Tumor Necrosis Factor Family Member 6，Apoptosis (APO-1) Antigen Ligand 1，CD178 Antigen，ALPS1B，TNLG1A，FasL，Fas Ligand Protein，SPPL2A-processed FasL form，APT1LG1，Tumor Necrosis Factor (Ligand) Superfamily， Member 6，Tumor Necrosis Factor Ligand 1A
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Fas Ligand Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (1)Cynomolgus / Rhesus macaque (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
FAL-H5241	Human	HEK293	Human Fas Ligand / TNFSF6 Protein, His Tag, premium grade				In den Warenkorb legen
FAL-H5246	Cynomolgus / Rhesus macaque	HEK293	Cynomolgus / Rhesus macaque Fas Ligand / TNFSF6 Protein, His Tag, premium grade				In den Warenkorb legen

Gesamtmenge2

Fas Ligand Molekülhintergrund

Fas ligand is also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain. Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Apoptosis triggered by Fas-Fas ligand binding plays a fundamental role in the regulation of the immune system. Its functions include:T-cell homeostasis, cytotoxic T-cell activity, immune privilege, maternal tolerance, tumor counterattack. Defective Fas-mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is associated with autoimmune lymphoproliferative syndrome (ALPS), a childhood disorder of apoptosis.

Fas Ligand Molekülalias

FASLG,ALPS1B,APT1LG1,CD178,CD95L,FASL,TNFSF6

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Asunercept	CAN-008; APG-101	Phase 2 Clinical	Apogenix Gmbh	Coronavirus Disease 2019 (COVID-19); Eye Diseases; Glioblastoma; Hematologic Neoplasms; Myelodysplastic Syndromes; Skin Diseases; Solid tumours	Details
Xelafaslatide	ONL-1204	Phase 2 Clinical	Onl Therapeutics	Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment	Details
M3T01	M3T01	Phase 1 Clinical	Providence Health & Services	Solid tumours	Details